Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 02, 2021 16:04 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced...
July 29, 2021 08:00 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
July 01, 2021 16:05 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
June 01, 2021 16:05 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
May 26, 2021 08:00 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced...
May 19, 2021 17:30 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021

Latest data from study TK216-01 remain encouraging, are consistent with previous results, and are updated over data contained in ASCO Abstract #11500 released todayTwo patients who achieved a complete...
May 19, 2021 17:01 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021

Latest data from the CIRLL study to be presented at ASCO 2021 remain encouraging, demonstrate good, continued enrollment, are consistent with previous results and are updated over data contained in...
May 17, 2021 16:01 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
May 06, 2021 16:01 ET | Source: Oncternal Therapeutics

Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results

Interim results of a Phase 1b trial of cirmtuzumab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer compare favorably to historical single-agent paclitaxel...
May 03, 2021 16:01 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...